Released Nov 7, 2024, before the open
10-Q filed Nov 7, 2024, 38 days after period end · 0000950170-24-122782
Q3 2024 · 10-Q
Revenue$196.61M$196.61M +6.8% vs Q3 2023−1.0% vs Q2 2024
Net Income-$27.39M-$27.39M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.71-$0.71 N/M vs Q3 2023N/M vs Q2 2024
Gross Profit$135,053,000+12.8%
Operating Income-$18,899,000N/M
Operating Cash Flowderived$11,671,000+2,346.8%
Free Cash Flowderived$6,349,000N/M
Margins · derived
Gross margin68.7%+3.6 pt vs Q3 2023
Operating margin-9.6%+3.7 pt vs Q3 2023
Net margin-13.9%+1.8 pt vs Q3 2023
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $196.61M | $184.01M | $114.00M | $112.43M |
| Net Income | -$27.39M | -$28.86M | -$10.72M | -$2.17M |
| EPS Diluted | -$0.71 | -$0.77 | -$0.53 | $0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR